Antimicrobial susceptibility profile of neisseria gonorrhoeae isolated from patients attending a std facility in maputo, mozambique

Sexually Transmitted Diseases

Volumn 36, Issue 6, 2009, Pages 341-343

  Apalata, Teke ^a   Zimba, Tomas F ^a,b   Sturm, Willem A ^a   Moodley, Prashini ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b MAPUTO CENTRAL HOSPITAL   (Mozambique)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; KANAMYCIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPECTINOMYCIN; TETRACYCLINE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; FEMALE; GONORRHEA; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOZAMBIQUE; NEISSERIA GONORRHOEAE; NONHUMAN; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; URETHRA; URETHRITIS; UTERINE CERVIX; VAGINA DISCHARGE;

ANTI-BACTERIAL AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GONORRHEA; HUMANS; KANAMYCIN; MALE; MICROBIAL SENSITIVITY TESTS; MOZAMBIQUE; NEISSERIA GONORRHOEAE; PENICILLINS; PRACTICE GUIDELINES AS TOPIC; URETHRITIS;

EID: 84868973271     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181982e3c     Document Type: Article

References (23)

1. World Health Organization programme for sexually transmitted diseases, Global Programme on AIDS. Recommendations for the management of sexually transmitted diseases. Geneva: WHO, 1994. WHO/GPA/TEM/94.
2. Tapsall J. Antimicrobial resistance in Neisseria gonorrhoeae. Geneva: WHO, 2001. WHO/CDS/CSR/DRS/2001.3.
3. World Health Organization. Sexually transmitted diseases treatment strategies. Geneva: WHO, 1989. WHO/VDT/89.
4. World Health Organization. Guidelines for the management of sexually transmitted infections. Geneva: WHO, 2003. Available at: http://www. emro.who.int/aiecf/web79.pdf. Accessed April 14, 2008.
5. Gerbase AC, Rowley JT, Heymann DHL, et al. Global prevalence and incidence estimates of selected curable STDs. Sex Transm Infect 1998; 74(suppl 1):S12-S16.
6. Johnson SR, Morse SA. Antibiotic resistance in Neisseria gonorrhoeae: Genetics and mechanisms of resistance. STD laboratory program, Centres for Diseases Control, Atlanta, GA 30333. Sex Transm Dis 1988; 15:217-224.
7. Moodley P, Martin IMC, Pillay K, et al. Molecular epidemiology of recently emergent ciprofloxacin-resistant Neisseria gonorrhoeae in South Africa. Sex Transm Dis 2006; 33:357-360.
8. Moodley P, Pillay C, Goga R, et al. Evolution in the trends of antimicrobial resistance in Neisseria gonorrhoeae isolated in Durban over a 5 year period: Impact of the introduction of the syndromic management. J Antimicrob Chemother 2001; 48:853-859.
9. Van Dyck E, Crabbé F, Nzila N, et al. Increasing resistance of Neisseria gonorrhoeae in West and Central Africa: Consequences on therapy of gonococcal infection. Sex Transm Dis 1997; 24:32-37.
10. Osoba AO, Johnston NA, Ogunganjo BO, et al. Plasmid profile of Neisseria gonorrhoeae in Nigeria and efficacy of spectinomycin in treating gonorrhea. Genitourin Med 1987; 63:1-5.
11. Meless H, Abegaze B. Drug susceptibility of Neisseria gonorrhoeae isolates from patients attending clinics for STDs in Addis Ababa. East Afr Med J 1997; 74:447-449.
12. Rui Bastos. Programma Nacional de Controle das DTS/SIDA. Maputo, Mozambique: PNCDTS/ SIDA Ministry of Health, 2002.
13. Bogaerts J, Tello WM, Akingeneye J, et al. Effectiveness of norfloxacin and ofloxacin for treatment of gonorrhoea and decrease of in vitro susceptibility to quinolones overtime in Rwanda. Genitourin Med 1993; 69:196-200.
14. Moodley P, Moodley D, Sturm AW. Ciprofloxacin-resistant Neisseria gonorrhoeae in South Africa. Int J Antimicrob Agents 2004; 24:192-193.
15. Moodley P, Sturm AW. Ciprofloxacin-resistant gonorrhoea in South Africa. Lancet 2005; 366:1159.
16. Mbofana FS, Brito FJ, Saifodine A, et al. Syndromic management of sexually transmitted diseases at primary care level, Mozambique. Sex Transm Infect 2002; 78:E2.
17. National Committee for Clinical Laboratory Standards. Performance standard for antimicrobial susceptibility testing. Ninth Informational Supplement M2-A6. Villanova, PA: NCCLS, 1999.
18. Van Dyck E, Meheus AZ, Piot P. Laboratory Diagnosis of Sex Transm Dis. Geneva, Switzerland: World Health Organization, 1999.
19. Knapp JS, Wongba C, Limpakarnjanarat K, et al. Antimicrobial susceptibilities of strains of Neisseria gonorrhoeae in Bangkok, Thailand: 1994-1995. Sex Transm Dis 1997; 24:142-148
20. Vorobieva V, Firsova N, Ababkova T, et al. Antibiotic susceptibility of Neisseria gonorrhoeae in Arkhangelsk, Russia. Sex Transm Infect 2007; 83:133-135.
21. Lesmana M, Lebron CI, Taslim D, et al. In vitro antibiotic susceptibility of Neisseria gonorrhoeae in Jakarka, Indonesia. J Antimicrob Chemother 2001; 45:359-362.
22. Marta C de Castillo, Olga A de Saab, Norma P de Fernandez, et al. Agar dilution method for susceptibility testing of Neisseria gonorrhoeae. Mem Inst Oswaldo Cruz 1996; 91:789-793.
23. Mbwana J, Mhalu F, Mwakagile D, et al. Susceptibility pattern of Neisseria gonorrhoeae to antimicrobial agents in Dares Salaam. East Afr Med J 1999; 76:330-334.